Trial intelligence / Profile preview

Lavender Oil Chest Wraps for Bronchiolitis

NCT06108648Phase 4

Key facts

Status: Recruiting
Start: Dec 2023
Primary completion: Mar 2026
Countries: 1
Modality: Small Molecules

Drugs: Silexan
Conditions: bronchiolitis

Overview

Phase 4, randomised, open-label trial of Silexan in bronchiolitis (2 arms). Primary endpoint: Cough frequency up to 2 days. Started Dec 2023; status: recruiting.

Design

2 arms

Study design: RandomizedOpen-label

Lavender oil
Lavender essential oil chest wrap added to standard care.
Control
Standard care alone.

Who it enrols

Infants hospitalized with a clinical diagnosis of bronchiolitis (respiratory distress and fine crackles). Exclusion criteria include underlying heart/lung disease, >3 episodes of bronchiolitis, ICU admission, and skin lesions on the chest.

Endpoints

Primary

Cough frequencyUp to 2 days

Secondary

Crying episodesUp to 2 days
Respiratory rate4 hours
Oxygen supplementation requirementDischarge
Oxygen supplementation durationDischarge
Maximum oxygen supplementationDischarge
Hospital length of stayDischarge
Parental satisfactionDischarge
Impact on parentsDischarge

Beyond the preview

Go deeper on NCT06108648.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06108648.